SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic : Conclusions for crisis response at a high-volume oncology center.
Asymptomatic infection
Cancer patient care
Polymerase chain reaction (PCR)
Safety measure
Testing strategy
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
16
03
2021
accepted:
21
07
2021
pubmed:
20
8
2021
medline:
18
9
2021
entrez:
19
8
2021
Statut:
ppublish
Résumé
During the second wave of the coronavirus disease 2019 (COVID-19) pandemic Austria suffered one of the highest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rates worldwide. We report performance parameters of a SARS-CoV‑2 screening program established for cancer outpatients at our center. Institutional policy recommended routine biweekly SARS-CoV‑2 testing. Adherence to the testing recommendation during the second wave of the COVID-19 pandemic between 1 October and 30 November 2020 was analyzed. The SARS-CoV‑2 infection rate during first wave period (21 March to 4 May 2020) was compared to the one during second wave. A total of 1577 cancer patients were seen at our outpatient clinic during the second wave. In 1079/1577 (68.4%) patients, at least 1 SARS-CoV2 test was performed. Overall 2833 tests were performed, 23/1577 (1.5%, 95% confidence interval, CI 1.0-2.2%) patients were tested positive for SARS-CoV‑2, which indicates a significant increase compared to the first wave (4/1016; 0.4%, 95% CI 0.1-1.0%) with an odds ratio of 3.9 (95% CI 1.5-10.1; p < 0.005). Patients undergoing active anticancer treatment (172/960; 17.9% not tested) were more likely to have undergone a SARS-CoV‑2 test than patients in follow-up or best supportive care (326/617; 52.8% not tested p < 0.001). Furthermore, patients with only 1 visit within 4 weeks were more likely to not have undergone a SARS-CoV‑2 test (386/598; 64.5%) compared to patients with 2 or more visits (112/979; 11.4%; p < 0.001). The projected number of patients with undetected SARS-CoV‑2 infection during the study period was 5. We identified clinical patient parameters influencing SARS-CoV‑2 testing coverage in cancer outpatients. Our data can provide information on generation of standard operating procedures and resource allocation during subsequent infection waves.
Sections du résumé
BACKGROUND
BACKGROUND
During the second wave of the coronavirus disease 2019 (COVID-19) pandemic Austria suffered one of the highest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rates worldwide. We report performance parameters of a SARS-CoV‑2 screening program established for cancer outpatients at our center.
METHODS
METHODS
Institutional policy recommended routine biweekly SARS-CoV‑2 testing. Adherence to the testing recommendation during the second wave of the COVID-19 pandemic between 1 October and 30 November 2020 was analyzed. The SARS-CoV‑2 infection rate during first wave period (21 March to 4 May 2020) was compared to the one during second wave.
RESULTS
RESULTS
A total of 1577 cancer patients were seen at our outpatient clinic during the second wave. In 1079/1577 (68.4%) patients, at least 1 SARS-CoV2 test was performed. Overall 2833 tests were performed, 23/1577 (1.5%, 95% confidence interval, CI 1.0-2.2%) patients were tested positive for SARS-CoV‑2, which indicates a significant increase compared to the first wave (4/1016; 0.4%, 95% CI 0.1-1.0%) with an odds ratio of 3.9 (95% CI 1.5-10.1; p < 0.005). Patients undergoing active anticancer treatment (172/960; 17.9% not tested) were more likely to have undergone a SARS-CoV‑2 test than patients in follow-up or best supportive care (326/617; 52.8% not tested p < 0.001). Furthermore, patients with only 1 visit within 4 weeks were more likely to not have undergone a SARS-CoV‑2 test (386/598; 64.5%) compared to patients with 2 or more visits (112/979; 11.4%; p < 0.001). The projected number of patients with undetected SARS-CoV‑2 infection during the study period was 5.
CONCLUSION
CONCLUSIONS
We identified clinical patient parameters influencing SARS-CoV‑2 testing coverage in cancer outpatients. Our data can provide information on generation of standard operating procedures and resource allocation during subsequent infection waves.
Identifiants
pubmed: 34410467
doi: 10.1007/s00508-021-01927-7
pii: 10.1007/s00508-021-01927-7
pmc: PMC8375465
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
909-914Informations de copyright
© 2021. The Author(s).
Références
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
J Clin Virol. 2020 Aug;129:104537
pubmed: 32659712
J Clin Microbiol. 2021 Jul 19;59(8):e0108021
pubmed: 33972455
N Engl J Med. 2020 Feb 27;382(9):872-874
pubmed: 31991079
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
Nature. 2021 Feb;590(7844):134-139
pubmed: 33348340
BMC Cancer. 2020 Dec 7;20(1):1194
pubmed: 33287747
Nat Cancer. 2020 Oct;1(10):965-975
pubmed: 35121871
Clin Chem Lab Med. 2020 Dec 16;59(5):987-994
pubmed: 33554519
ESMO Open. 2020 Sep;5(5):e000889
pubmed: 32878898
JCO Glob Oncol. 2020 Sep;6:1461-1471
pubmed: 32997537
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
J Natl Cancer Inst. 2021 Jul 1;113(7):820-822
pubmed: 32797188
J Clin Virol. 2007 Oct;40(2):93-8
pubmed: 17766174
JMIR Cancer. 2020 Oct 29;6(2):e21697
pubmed: 33027039
J Clin Oncol. 2020 Oct 20;38(30):3547-3554
pubmed: 32795227
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Clin Cancer Res. 2020 Sep 15;26(18):4737-4742
pubmed: 32616498
Ann Oncol. 2020 Jul;31(7):832-834
pubmed: 32278879
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
JCO Clin Cancer Inform. 2020 Nov;4:1059-1071
pubmed: 33253013